Epithelial-mesenchymal transition in prostate cancer: an overview
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
// Micaela Montanari 1,2 , Sabrina Rossetti 1 , Carla Cavaliere 1,3 , Carmine D’Aniello 1,4 , Maria Gabriella Malzone 1,5 , Daniela Vanacore 1 , Rossella Di Franco 1,6 , Elvira La Mantia 1,5 , Gelsomina Iovane 1,7 , Raffaele Piscitelli 1 , Raffaele Muscariello 8 , Massimiliano Berretta 9 , Sisto Perdonà 8 , Paolo Muto 6 , Gerardo Botti 5,10 , Attilio Antonio Montano Bianchi 11 , Bianca Maria Veneziani 2 and Gaetano Facchini 1,7 1 Progetto ONCONET2.0, Linea Progettuale 14 per L’implementazione della Prevenzione e Diagnosi Precoce del Tumore alla Prostata e Testicolo, Regione Campania, Italy 2 Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”, Naples, Italy 3 Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto, Taranto, Italy 4 Division of Medical Oncology, A.O.R.N. dei COLLI “Ospedali Monaldi-Cotugno-CTO”, Naples, Italy 5 Pathology Unit, Istituto Nazionale Tumori “Fondazione G. Pascale”, IRCCS, Naples, Italy 6 Radiation Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori ‘Fondazione Giovanni Pascale’, IRCCS, Naples, Italy 7 Department of Uro-Gynaecological Oncology, Division of Medical Oncology, Istituto Nazionale Tumori ‘Fondazione G. Pascale’, IRCCS, Naples, Italy 8 Department of Uro-Gynaecological Oncology, Division of Urology, Istituto Nazionale Tumori ‘Fondazione G. Pascale’, IRCCS, Naples, Italy 9 Department of Medical Oncology, CRO Aviano, National Cancer Institute, Aviano, Italy 10 Scientific Directorate, Istituto Nazionale Tumori ‘Fondazione G. Pascale’, IRCCS, Naples, Italy 11 Directorate-General for Management, Istituto Nazionale Tumori ‘Fondazione G. Pascale’, IRCCS, Naples, Italy Correspondence to: Micaela Montanari, email: // Keywords : prostate cancer; epithelial-mesenchymal transition; androgen receptor; TGF-β signaling; EGF/EGFR Received : November 10, 2016 Accepted : February 15, 2017 Published : February 25, 2017 Abstract Prostate cancer is a main urological disease associated with significant morbidity and mortality. Radical prostatectomy and radiotherapy are potentially curative for localized prostate cancer, while androgen deprivation therapy is the initial systemic therapy for metastatic prostate disease. However, despite temporary response, most patients relapse and evolve into castration resistant cancer. Epithelial-mesenchymal transition (EMT) is a complex gradual process that occurs during embryonic development and/or tumor progression. During this process, cells lose their epithelial characteristics and acquire mesenchymal features. Increasing evidences indicate that EMT promotes prostate cancer metastatic progression and it is closely correlated with increased stemness and drug resistance. In this review, we discuss the main molecular events that directly or indirectly govern the EMT program in prostate cancer, in order to better define the role and the mechanisms underlying this process in prostate cancer progression and therapeutic resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091 · cited 1×
“Conserved zinc finger transcription factors, controlled by upstream TGF-β activities, have been reported to induce EMT functions [82,83].”
BackgroundInhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121 · cited 1×
“Conserved zinc finger transcription factors, controlled by upstream TGF-β activities, have been reported to induce EMT functions [82,83].”
BackgroundEstrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857 · cited 1×
“After binding with estrogen or estrogen-like compounds, ER-α and -β can homo- or heterodimerize and in the nucleus activate different signaling pathways [46].”
BackgroundAndrogen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Signaling mechanisms of the epithelial-mesenchymal transition
Gonzalez, D. M., & Medici, D. (2014) · Science Signaling · doi:10.1126/scisignal.2005189 · Cited by 1,721
TGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401 · cited 1×
“Thus, TGF-β pathways in fibroblasts promotes prostate cancer by modulating the adjacent epithelial cell growth and its oncogenic ability [76, 77].”
BackgroundAndrogen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286 · cited 2×
“TGF-β is able to regulate AR gene targets in a close crosstalk with androgens, with AR-dependent outcomes [80, 41].”
BackgroundThe tale of transforming growth factor‐beta (TGFβ) signaling: A soigné enigma
Chaudhury, A., & Howe, P. H. (2009) · IUBMB Life · doi:10.1002/iub.239 · Cited by 105 · cited 1×
“Smad-dependent pathway promotes TGF-β tumor suppressive roles, whereas the activation of Smad-independent pathways, along with the loss of TGF-β tumor suppressor roles, is responsible for its pro-oncogenic activity [67,68].”
Background
Cited by
EMT, cancer stem cells and autophagy; The three main axes of metastasis
Babaei, G., Aziz, S. G.-G., & Jaghi, N. Z. Z. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110909 · Cited by 506
Circulating tumour cells for early detection of clinically relevant cancer
Lawrence, R., Watters, M., Davies, C. R., Pantel, K., & Lu, Y.-J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00781-y · Cited by 370
Prostate cancer reactivates developmental epigenomic programs during metastatic progression
Pomerantz, M. M., Qiu, X., Zhu, Y., Takeda, D. Y., Pan, W., Baca, S. C., Gusev, A., Korthauer, K. D., Severson, T. M., Ha, G., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0664-8 · Cited by 268
Metadata
- Authors
- Montanari, M., Rossetti, S., Cavaliere, C., D’Aniello, C., Malzone, M. G., Vanacore, D., Franco, R. D., Mantia, E. L., Iovane, G., Piscitelli, R., Muscariello, R., Berretta, M., Perdonà, S., Muto, P., Botti, G., Bianchi, A. A. M., Veneziani, B. M., & Facchini, G.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-02-25
- Volume
- 8
- Issue
- 21
- Pages
- 35376-35389
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2590318769
- Cited by
- 180
- References
- 12
- FWCI
- 17.01
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.